Unlocking Hard-to-Drug Targets: How VHH Antibodies Overcome Drug Discovery Barriers For decades, certain drug targets have been labeled as “undruggable” due to their complex structures, lack of accessible binding sites, or dynamic conformational changes....
A Competitive and Ethical Future in Discovery Pharmaceutical and biotech R&D is undergoing a notable shift in how therapeutic antibodies are discovered. Traditionally, antibody generation relied on immunizing animals (e.g. mice, rabbits, or even llamas) to raise...
Isogenica named in Business Weekly’s Ones2Watch In Q1 2025, Business Weekly published its latest Killer50 showcase – a long-standing benchmark for innovation in UK life sciences Recognition in a Difficult Quarter In Q1 2025, Business Weekly...
Building the next generation of precision oncology medicines Biologic therapies have reshaped oncology, but they come with real limitations. Traditional monoclonal antibodies are large, complex molecules that can struggle with tumor penetration, slow development...
Avoiding Freedom-to-Operate Pitfalls in Antibody Discovery In antibody discovery, identifying a promising therapeutic candidate is only part of the challenge, and even that is no easy task. For well-established drug targets, securing freedom-to-operate (FTO) is...
Why Biotech Leaders Choose Cambridge UK for Antibody Discovery In an increasingly complex global R&D environment, not only speed and cost, but also risk management should be considered when choosing to partner with a clinical research organization (CRO). Global...
